Rechercher
image du produit
Gastrointestinal Endoscopy

S'abonner

A retrograde-viewing device improves detection of adenomas in the colon: a prospective efficacy evaluation (with videos) - 22/08/11

Doi : 10.1016/j.gie.2009.09.043 
Jerome D. Waye, MD ⁎, Russell I. Heigh, MD, David E. Fleischer, MD, Jonathan A. Leighton, MD, Suryakanth Gurudu, MD, Leslie B. Aldrich, MD, Jiayi Li, MD, Sanjay Ramrakhiani, MD, Steven A. Edmundowicz, MD, Dayna S. Early, MD, Sreenivasa Jonnalagadda, MD, Robert S. Bresalier, MD, William R. Kessler, MD, Douglas K. Rex, MD
Current affiliations: Mount Sinai Medical Center (J.D.W.), New York, New York, Mayo Clinic Scottsdale (R.I.H., D.E.F., J.A.L., S.G.), Scottsdale, Arizona, University of Michigan (L.B.A.), Ann Arbor, Michigan, Camino Medical Group and El Camino Hospital (J.L., S.R.), Mountain View, California, Washington University (S.A.E., D.S.E., S.J.), St. Louis, Missouri, University of Texas M.D. Anderson Cancer Center (R.S.B.), Houston, Texas, Indiana University Medical Center (W.R.K., D.K.R.), Indianapolis, Indiana, USA 

Reprint requests: Jerome D. Waye, MD, 650 Park Avenue, New York, NY 10021.

New York, New York, Scottsdale, Arizona, Ann Arbor, Michigan, Mountain View, California, St. Louis, Missouri, Houston, Texas, Indianapolis, Indiana, USA

Abstract

Background

Colonoscopy may fail to detect neoplasia located on the proximal sides of haustral folds and flexures. The Third Eye Retroscope (TER) provides a simultaneous retrograde view that complements the forward view of a standard colonoscope.

Objective

To evaluate the added benefit for polyp detection during colonoscopy of a retrograde-viewing device.

Design

Open-label, prospective, multicenter study evaluating colonoscopy by using a TER in combination with a standard colonoscope.

Setting

Eight U.S. sites, including university medical centers, ambulatory surgery centers, a community hospital, and a physician’s office.

Patients

A total of 249 patients (age range 55-80 years) presenting for screening or surveillance colonoscopy.

Interventions

After cecal intubation, the disposable TER was inserted through the instrument channel of the colonoscope. During withdrawal, the forward and retrograde video images were observed simultaneously on a wide-screen monitor.

Main Outcome Measurements

The number and sizes of lesions (adenomas and all polyps) detected with the standard colonoscope and the number and sizes of lesions found only because they were first detected with the TER.

Results

In the 249 subjects, 257 polyps (including 136 adenomas) were identified with the colonoscope alone. The TER allowed detection of 34 additional polyps (a 13.2% increase; P < .0001) including 15 additional adenomas (an 11.0% increase; P < .0001). For lesions 6 mm or larger, the additional detection rates with the TER for all polyps and for adenomas were 18.2% and 25.0%, respectively. For lesions 10 mm or larger, the additional detection rates with the TER for all polyps and for adenomas were 30.8% and 33.3%, respectively. In 28 (11.2%) individuals, at least 1 additional polyp was found with the TER. In 8 (3.2%) patients, the polyp detected with the TER was the only one found. Every polyp that was detected with the TER was subsequently located with the colonoscope and removed. For all polyps and for adenomas, the additional detection rates for the TER were 9.7%/4.1% in the left colon (the splenic flexure to the rectum) and 16.5%/14.9% in the right colon (the cecum to the transverse colon), respectively.

Limitations

There was no randomization or comparison with a separate control group.

Conclusions

A retrograde-viewing device revealed areas that were hidden from the forward-viewing colonoscope and allowed detection of 13.2% additional polyps, including 11.0% additional adenomas. Additional detection rates with the TER for adenomas 6 mm or larger and 10 mm or larger were 25.0% and 33.3%, respectively. (Clinical trial registration number: NCT00657371.)

Le texte complet de cet article est disponible en PDF.

Abbreviation : TER


Plan


 DISCLOSURE: The following authors disclosed financial relationships relevant to this publication: R.I. Heigh: Research grant fromAvantis Medical Systems. D.E. Fleischer: Research grants from BARRX Medical, Olympus, and Fujinon. J.A. Leighton: Research grant from Olympus and Fujinon; research grant from and consultant for Given Imaging; consultant for Intromedic. J. Li: Research grant from Avantis Medical Systems. S. Ramrakhiani: Research grant from Avantis Medical Systems. S.A. Edmundowicz: Consultant for Olympus; member of medical advisory board of and stockholder in Spirus. S. Jonnalagadda: Center of Excellence speaker for Olympus. D.K. Rex: Research grant from and speaker for Olympus; research grant from and member of the Scientific Advisory Board of Given Imaging; member of the Scientific Advisory Board of and stockholder in Avantis Medical Systems; member of the Scientific Advisory Board of GI View, American BioOptics, CheckCap, and Softscope. The other authors disclosed no financial relationships relevant to this publication.
 If you would like to chat with an author of this article, you may contact Dr. Waye at jdwaye@aol.com.


© 2010  American Society for Gastrointestinal Endoscopy. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

    •

  • Contenu

    •

Vol 71 - N° 3

P. 551-556 - mars 2010 Retour au numéro
Article précédent Article précédent
  • Impact of experience with a retrograde-viewing device on adenoma detection rates and withdrawal times during colonoscopy: the Third Eye Retroscope study group
  • Daniel C. DeMarco, Elizabeth Odstrcil, Luis F. Lara, David Bass, Chase Herdman, Timothy Kinney, Kapil Gupta, Leon Wolf, Thomas Dewar, Thomas M. Deas, Manoj K. Mehta, M. Badar Anwer, Randall Pellish, J. Kent Hamilton, Daniel Polter, K. Gautham Reddy, Ira Hanan
| Article suivant Article suivant
  • Adenoma detection and retroscopy
  • James S. Barthel

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.

Tout le contenu de ce site: Copyright © 2026 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.